Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
EMERYVILLE, Calif., May 31, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY.
Zogenix Presentation Details
| Date: | Wednesday, June 7, 2017 |
| Time: | 2:00 pm Eastern Time / 11:00 am Pacific Time |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
